Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986340 + nivolumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BMS-986340 + nivolumab is a combination of two immunotherapy antibodies under investigation for the treatment of advanced solid tumors. BMS-986340 is an investigational monoclonal antibody being studied for safety and efficacy, particularly in enhancing the immune system's ability to target tumor cells. Nivolumab, marketed as Opdivo, is an approved immunotherapy antibody that blocks the PD-1 immune checkpoint to boost anti-tumor immune responses. The combination is currently being tested in early clinical trials to determine safety, tolerability, optimal dosing, and anti-tumor activity in several advanced and refractory solid tumors[1][5][2][3][7].
- Brand names
- Opdivo
- Other names
- anti-CCR8 mAb + anti-PD-1 mAb
02
Targets
CCR8PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on BMS-986340 + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986340 + nivolumab.